ACC

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

A small, multi-country analysis of women of child-rearing age has found that these patients experience limits on activities of daily living, challenges with the healthcare system and a high overall financial burden.

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding events or who need urgent surgery.

Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has been studied extensively in patients with mildly reduced or preserved ejection fraction.

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with chronic kidney disease as those without it, and there are signals that it has benefits for renal function.

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent clinical trials have reinforced the potential of Winrevair (sotatercept) as a breakthrough in pulmonary arterial hypertension (PAH) treatment.

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.

Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.

Factor XI Inhibitors are the alternative to DOACs, which are highly effective at preventing strokes. However, their bleeding risks often limit their use, especially in high-risk patients.

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) narrowed in the FAME 3 five-year follow-up study, but there were fewer myocardial infarctions and repeat revascularizations in the PCI group.

In an interview with Managed Healthcare Executive, Christian T. Ruff, M.D., M.P.H., director of general cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School, addressed the uncertainty of the bleeding risks of abelacimab compared to rivaroxaban and highlighted abelacimab’s safety profile.

In this second part of his interview with Managed Healthcare Executive, John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, discusses lifestyle management and GLP-1s.

The rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was 30% lower among patients receiving nurse-led follow-up care after acute coronary syndrome.

John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 per month would make the GLP-1s cost-effective as a prevention measure.

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and all-cause death.

The largest randomized study of fluid intake restrictions showed no benefit from the restrictions, according to its senior author.

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults with type 2 diabetes. A regulatory decision is anticipated in 2025.

The results are one of 10 from the FINEARTS-HF that are scheduled for presentation at the

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to bleeding risks.

A new analysis presented at the ACC 2025 meeting also finds that the new prices for heart failure drugs negotiated through Medicare will reduce hospitalizations.